The company plans to in particular use the funds to prepare a clinical trial of their anti-FcγRIIB antibody BI-1206 for the treatment of Non-Hodgkin’s Lymphoma. The Board of Directors of

The Danish biotech company Cysbio has received two grants from the EU’s “Horizon 2020” program worth 4.4 million euros. According to the management, these grants will accelerate the development work

Immunicum has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the treatment of Soft Tissue

BioInvent International has restructured a clinical development agreement with Cancer Research UK (CRUK) for its anti-FcγRIIB antibody, BI-1206. In exchange for a one-time payment, the revised deal simplifies and reduces

Nanexa has entered into an investment agreement with Applied Ventures, the venture capital arm of Applied Materials, whereby Applied Ventures intends to invest up to USD 3 million in Nanexa

Investors in the Directed Share Issue are a wide range of Swedish and international investors, including AFA Försäkring, Swedbank Robur, Invus Public Equities LP, Point72 Asset Management, Handelsbanken Fonder and

Cantargia and BioInvent International have announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis. CAN10 is

Alligator Bioscience has announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND approval by the US Food and Drug Administration (FDA) is a prerequisite to

Immunicum has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for the company’s lead candidate, ilixadencel. Ilixadencel is a cell-based, off-the-shelf immune primer, for the

Single Technologies has announced the completion of an oversubscribed €5 million share issue to existing and new shareholders. Among the new investors are Jens von Bahr, Rothesay Ltd, Carl-Henric Svanberg